Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    2211675 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine
Condition: Malaria
Interventions: Biological: AMA1-C1/Alhydrogel + CPG 7909 (Saline);   Biological: AMA1-C1/Alhydrogel + CPG 7909 (Phosphate);   Drug: AMA1-C1/Alhydrogel + CPG 7909
2 Completed Malaria Vaccine in Children in Mali
Condition: Malaria
Intervention: Drug: AMA1-C1/Alhydrogel Malaria Vaccine
3 Completed Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)
Conditions: Healthy Volunteer;   HV
Intervention: Drug: AMA1-C1/Alhydrogel + CpG 7909
4 Completed Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
Condition: Malaria
Intervention: Drug: AMA1-C1/ISA 720

Indicates status has not been verified in more than two years